PDS Biotechnology (NASDAQ:PDSB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of PDS Biotechnology (NASDAQ:PDSB) from a sell rating to a hold rating in a research note released on Saturday.

PDSB has been the topic of a number of other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of PDS Biotechnology in a research note on Wednesday, April 15th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $9.00.

PDS Biotechnology Price Performance

PDS Biotechnology stock opened at $0.73 on Friday. PDS Biotechnology has a 52-week low of $0.51 and a 52-week high of $1.55. The firm has a fifty day moving average of $0.85 and a 200-day moving average of $0.87. The firm has a market capitalization of $40.88 million, a P/E ratio of -1.09 and a beta of 1.62. The company has a quick ratio of 2.26, a current ratio of 2.26 and a debt-to-equity ratio of 2.73.

PDS Biotechnology (NASDAQ:PDSB) last posted its earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02. As a group, analysts predict that PDS Biotechnology will post -0.52 EPS for the current year.

Hedge Funds Weigh In On PDS Biotechnology

A number of institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC purchased a new position in PDS Biotechnology in the 4th quarter valued at about $2,182,000. Commonwealth Equity Services LLC increased its position in shares of PDS Biotechnology by 117.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock worth $151,000 after acquiring an additional 106,300 shares during the last quarter. Geode Capital Management LLC increased its position in shares of PDS Biotechnology by 8.0% during the fourth quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock worth $401,000 after acquiring an additional 38,399 shares during the last quarter. Susquehanna International Group LLP lifted its stake in shares of PDS Biotechnology by 603.7% in the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after acquiring an additional 80,937 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its stake in shares of PDS Biotechnology by 116.1% in the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock worth $295,000 after acquiring an additional 156,662 shares in the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.